Gut Microbiota and Alzheimer's Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03827733|
Recruitment Status : Recruiting
First Posted : February 1, 2019
Last Update Posted : April 19, 2021
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Gut Microbiota and Alzheimer's Diseases|
|Actual Study Start Date :||February 1, 2018|
|Estimated Primary Completion Date :||December 31, 2022|
|Estimated Study Completion Date :||December 31, 2022|
Participants who are diagnosed with AD.
Partners of the AD patients
Partners of AD patients who live together with the AD patients.
Elderly participants with normal cognition
Community dwelling elderly with normal cognition and with AD.
- Gut beta-amyloid 42 [ Time Frame: Through study completion, an average of 4 year ]Gut amyloid-beta 42 will be determined by digital ELISA, traditional ELISA and western blot.
- Gut microbiota [ Time Frame: Through study completion, an average of 4 year ]We will use DNA sequencing to define the profile of gut microbiota.
- Oral microbiota [ Time Frame: Through study completion, an average of 4 year ]We will use DNA sequencing to define the profile of gut microbiota.
- Cognitive function by Mini-mental State Examination (MMSE) [ Time Frame: through study completion, an average of 4 year ]We will assess the cognitive function in the participants using MMSE to promote the diagnosis of AD in these participants. The sum of MMSE ranges from 0 (worse) to 30 (better).
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03827733
|Contact: Yuan Shen, MD, PhDfirstname.lastname@example.org|
|Contact: Zhongyong Shi, MDemail@example.com|
|Shanghai Tenth People's Hospital||Recruiting|
|Shanghai, Shanghai, China, 200072|
|Contact: Yanxia Guo, M.D. 021-65982875 firstname.lastname@example.org|
|Principal Investigator:||Yuan Shen, MD, PhD||Shanghai 10th People's Hospital|